News

The United States ("U.S.") Patent and Trademark Office has granted its sixth patent and the Japan Patent Office has granted its first patent for the Company’s lead oncology

The facility will be used to support automated production of the company’s Arcelis-based personalized immunotherapy product candidates, beginning with AGS-003, the company’s lead oncology product candidate, currently being

Currently, there are no approved treatments for FA, which is a debilitating, life-shortening, degenerative neuro-muscular disorder affecting at least one in 50,000 people in the US. Most youngsters

The humanized monoclonal antibody, RPC4046 is directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications. Receptos president and chief executive officer Faheem

Utilizing Intrexon’s robust microbial-based expression system, the goal of the collaboration is to develop a consistent, scalable, and cost-effective process for the targeted complex API. "The power of

The Company owns a fifty percent interest in CRD. The Company participated in the formation of CRD in order to further the Company’s mission of advancing the use

The T-Force study is an open-label, multi-dose, two-week study of 36 subjects with Tourette syndrome. Children and adolescents will receive once-daily dosing of NBI-98854 during a two-week treatment

Prima will pay consideration of up to approximately US$28 M through a combination of cash, shares and warrants subject to the achievement of certain performance milestones. The transaction

Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million. Fiorinal and Fiorinal C are indicated for the relief